Buch, Englisch, Band 256, 378 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 587 g
Buch, Englisch, Band 256, 378 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 587 g
Reihe: Handbook of Experimental Pharmacology
ISBN: 978-3-030-22007-5
Verlag: Springer International Publishing
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie
Weitere Infos & Material
Preface.- Part 1. Bile acids as signaling molecules and their receptors.- 1. A short history of bile acid pharmacology.- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors.- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors.- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism.- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity.- Part 2. General pharmacology of bile acid activated receptors and their ligands.- 6. Modeling of bile acid activated receptors as a tool for pharmacological development.- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists.- 8. Non steroidal FXR ligands: current status and clinical applications.- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases.- Part 3. Bile acids and their derivatives as drugs.- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications.- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile.- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications.- Part 4. Bile acid activated receptors as therapeutic targets.- 13. Targeting FXR in cholestasis.- 14. FXR agonists for the treatment of NASH and other metabolic disorders.- 15. Targeting bile acids activated receptors in bariatric surgery.